Relationship between HER2 status and prognosis in women with brain metastases from breast cancer

International Journal of Radiation Oncology Biology Physics

Volumn 82, Issue 5, 2012, Pages

  Xu, Zhiyuan ^a   Marko, Nicholas F ^a   Chao, Sam T ^a   Angelov, Lilyana ^a   Vogelbaum, Michael A ^a   Suh, John H ^a   Barnett, Gene H ^a   Weil, Robert J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Hazards analysis; Kaplan Meier analysis; Lapatinib; Stereotactic radiosurgery; Surgery; Survival; Trastuzumab; Whole brain radiotherapy

Indexed keywords

KAPLAN-MEIER; LAPATINIB; STEREOTACTIC RADIOSURGERY; SURVIVAL; TRASTUZUMAB; WHOLE BRAIN RADIOTHERAPY;

DIAGNOSIS; MONOCLONAL ANTIBODIES; PATIENT MONITORING; RADIOTHERAPY; SURGERY; TUMORS;

DISEASES;

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; LAPATINIB; PROGESTERONE RECEPTOR; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; BREAST CANCER; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; DOSIMETRY; FEMALE; GENE AMPLIFICATION; HUMAN; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POST TREATMENT SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; RISK FACTOR; STEREOTACTIC RADIOSURGERY;

ADULT; AGED; BRAIN NEOPLASMS; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RADIOSURGERY; RECEPTOR, ERBB-2; RISK FACTORS; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84857290277     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2011.06.1968     Document Type: Article

References (50)

1. Weil RJ, Palmieri DC, Bronder JL, et al. Breast cancer metastasis to the central nervous system. Am J Pathol 2005;167:913-920. (Pubitemid 41416243)
2. Barnholtz-Sloan JS, Sloan AE, Davis FG, et al. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 2004; 22:2865-2872. (Pubitemid 41079905)
3. Miller KD, Weathers T, Haney LG, et al. Occult central nervous system involvement in patients with metastatic breast cancer: Prevalence, predictive factors and impact on overall survival. Ann Oncol 2003;14:1072-1077. (Pubitemid 36950171)
4. Gonzalez-Angulo AM, Cristofanilli M, Strom EA, et al. Central nervous system metastases in patients with high-risk breast carcinoma after multimodality treatment. Cancer 2004;101:1760-1766. (Pubitemid 39314738)
5. Hicks DG, Short SM, Prescott NL, et al. Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. Am J Surg Pathol 2006;30:1097-1104. (Pubitemid 44299342)
6. Evans AJ, James JJ, Cornford EJ, et al. Brain metastases from breast cancer: Identification of a high-risk group. Clin Oncol (R Coll Radiol) 2004;16:345-349. (Pubitemid 38967255)
7. Albiges L, Andre F, Balleyguier C, et al. Spectrum of breast cancer metastasis in BRCA1 mutation carriers: Highly increased incidence of brain metastases. Ann Oncol 2005;16:1846-1847. (Pubitemid 41631252)
8. Ryberg M, Nielsen D, Osterlind K, et al. Predictors of central nervous system metastasis in patients with metastatic breast cancer. A competing risk analysis of 579 patients treated with epirubicin-based chemotherapy. Breast Cancer Res Treat 2005;91:217-225. (Pubitemid 40896568)
9. Mahmoud-Ahmed AS, Suh JH, Lee SY, et al. Results of whole brain radiotherapy in patients with brain metastases from breast cancer: A retrospective study. Int J Radiat Oncol Biol Phys 2002;54:810-817.
10. Coussens L, Yang-Feng TL, Liao YC, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985;230:1132-1139. (Pubitemid 16169997)
11. Lin NU, Winer EP. Brain metastases: The HER2 paradigm. Clin Cancer Res 2007;13:1648-1655. (Pubitemid 46952930)
12. Menard S, Balsari A, Casalini P, et al. HER-2-positive breast carcinomas as a particular subset with peculiar clinical behaviors. Clin Cancer Res 2002;8:520-525. (Pubitemid 34193972)
13. Pritchard KI, Shepherd LE, O'Malley FP, et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 2006;354:2103-2111. (Pubitemid 43736610)
14. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244:707-712. (Pubitemid 19147683)
15. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792. (Pubitemid 32222155)
16. Soerjomataram I, Louwman MW, Ribot JG, et al. An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Res Treat 2008;107:309-330. (Pubitemid 351172108)
17. O'Meara W, Seidman A, Yamada Y, et al. Impact of HER2 status in breast cancer patients receiving stereotactic radiosurgery for brain metastases Abstr. J Clin Oncol 2005.
18. Bendell JC, Domchek SM, Burstein HJ, et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003;97:2972-2977. (Pubitemid 36676250)
19. Yau T, Swanton C, Chua S, et al. Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab. Acta Oncol 2006;45:196-201.
20. Stemmler HJ, Kahlert S, Siekiera W, et al. Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer. Breast 2006;15:219-225.
21. Clayton AJ, Danson S, Jolly S, et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 2004;91:639-643. (Pubitemid 39141617)
22. Niwinska A, Tacikowska M, Pienkowski T, et al. Frequency of asymptomatic brain metastases in Her-2 positive breast cancer patient. Breast Cancer Res Treat 2005;94:S181.
23. Pestalozzi BC, Zahrieh D, Price KN, et al. Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol 2006;17:935-944. (Pubitemid 43778983)
24. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-1672. (Pubitemid 41464705)
25. Ono M, Ando M, Yunokawa M, et al. Brain metastases in patients who receive trastuzumab-containing chemotherapy for HER2- overexpressing metastatic breast cancer. Int J Clin Oncol 2009;14: 48-52.
26. Park IH, Ro J, Lee KS, et al. Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer. Ann Oncol 2009;20:56-62.
27. Duchnowska R, Dziadziuszko R, Czartoryska-Arlukowicz B, et al. Risk factors for brain relapse in HER2-positive metastatic breast cancer patients. Breast Cancer Res Treat 2009;117:297-303.
28. Paterson C, McIntyre A, Canney PA. Does HER-2 over-expressing breast cancer have a predilection to metastasize to the brain? Clin Oncol (R Coll Radiol) 2009;21:635-636.
29. Andre F, Slimane K, Bachelot T, et al. Breast cancer with synchronous metastases: Trends in survival during a 14-year period. J Clin Oncol 2004;22:3302-3308. (Pubitemid 41103686)
30. Gennari A, Conte P, Rosso R, et al. Survival of metastatic breast carcinoma patients over a 20-year period: A retrospective analysis based on individual patient data from six consecutive studies. Cancer 2005;104:1742-1750. (Pubitemid 41437440)
31. Falkson G, Gelman RS, Leone L, et al. Survival of premenopausal women with metastatic breast cancer. Long-term follow-up of Eastern Cooperative Group and Cancer and Leukemia Group B studies. Cancer 1990;66:1621-1629. (Pubitemid 20355434)
32. Wolstenholme V, Hawkins M, Ashley S, et al. HER2 significance and treatment outcomes after radiotherapy for brain metastases in breast cancer patients. Breast 2008;17:661-665.
33. Burstein HJ, Lieberman G, Slamon DJ, et al. Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy. Ann Oncol 2005;16:1772-1777. (Pubitemid 41631239)
34. Stuschke M, Eberhardt W, Pottgen C, et al. Prophylactic cranial irradiation in locally advanced non-small-cell lung cancer after multimodality treatment: Long-term follow-up and investigations of late neuropsychologic effects. J Clin Oncol 1999;17:2700-2709. (Pubitemid 29415226)
35. Lin NU, Carey LA, Liu MC, et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2- positive breast cancer. J Clin Oncol 2008;26:1993-1999.
36. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355: 2733-2743. (Pubitemid 46021510)
37. Wong KK, Fracasso PM, Bukowski RM, et al. A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin Cancer Res 2009;15:2552-2558.
38. Chang EL, Wefel JS, Hess KR, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole- brain irradiation: A randomised controlled trial. Lancet Oncol 2009; 10:1037-1044.
39. Tubbs RR, Hicks DG, Cook J, et al. Fluorescence in situ hybridization (FISH) as primary methodology for the assessment of HER2 Status in adenocarcinoma of the breast: A single institution experience. Diagn Mol Pathol 2007;16:207-210. (Pubitemid 350196977)
40. Lal P, Salazar PA, Hudis CA, et al. HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: A single-institution experience of 2,279 cases and comparison of dual-color and single-color scoring. Am J Clin Pathol 2004;121: 631-636. (Pubitemid 38533994)
41. Wolf AC, Hammond EH, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007;131:18-43. (Pubitemid 46174133)
42. Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: Phase III results of the RTOG 9508 randomised trial. Lancet 2004;363:1665-1672. (Pubitemid 38670323)
43. Sperduto PW, Chao ST, Sneed PK, et al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: A multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys 2010;77:655-661.
44. Aoyama H, Shirato H, Tago M, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: A randomized controlled trial. JAMA 2006;295:2483-2491. (Pubitemid 43854963)
45. Vecht CJ, Haaxma-Reiche H, Noordijk EM, et al. Treatment of single brain metastasis: Radiotherapy alone or combined with neurosurgery? Ann Neurol 1993;33:583-590. (Pubitemid 23161878)
46. Patchell RA, Tibbs PA, Regine WF, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: A randomized trial. JAMA 1998;280:1485-1489.
47. Kased N, Binder DK, McDermott MW, et al. Gamma Knife radiosurgery for brain metastases from primary breast cancer. Int J Radiat Oncol Biol Phys 2009;75:1132-1140.
48. Colozza M, Minenza E, Gori S, et al. Extended survival of a HER-2- positive metastatic breast cancer patient with brain metastases also treated with intrathecal trastuzumab. Cancer Chemother Pharmacol 2009;63:1157-1159.
49. Bartsch R, Rottenfusser A, Wenzel C, et al. Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer. J Neurooncol 2007;85:311-317. (Pubitemid 350142522)
50. Kirsch DG, Ledezma CJ, Mathews CS, et al. Survival after brain metastases from breast cancer in the trastuzumab era. J Clin Oncol 2005;23:2114-2116. author reply 2116-2117.